MOLBIOMolbio Diagnostics Limited
Healthcare · Medical Devices · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Verna, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on MOLBIO — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 41.9% YoY
- • ROCE: 17.2%
- • Debt/Equity: 0.38
- • Trend strength (ADX): 31
- • 1-month vs NIFTY: +5.1% relative
- • Max drawdown (1y): 21%
Bull case
- • Revenue growth: 41.9% YoY
- • ROCE: 17.2%
- • Debt/Equity: 0.38
- • Trend strength (ADX): 31
Bear case
- • Valuation vs sector: P/E 88.1 vs sector 45.7
- • Dividend yield: 0.00%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Momentum is fading versus the broader market
- • Valuation vs sector: P/E 88.1 vs sector 45.7
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹101.19). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.